INTRODUCTION
Antiretroviral therapy (ART) has been a steppingstone in the treatment of AIDS, but is incapable of eradicating HIV, type 1 (HIV-1). Instead, latently infected cells persist in reservoir compartments, leading to viral rebound following ART interruption. HIV persistence is also due in part to the unique ability of HIV to evade therapeutics and host immune responses via high mutation rates, further complicating the development of a cure [1] . Alternative treatment options are, therefore, required to maintain virus remission in the absence of ART. Engineering of T cells with chimeric antigen receptors (CARs) directed against the envelope of HIV could improve the adaptive immune response against the virus, which is generally observed following HIV-1 infection, but is inefficient at controlling viremia. Despite the recent Food and Drug Administration (FDA) approval of CAR T-cell therapy for B-cell leukemia, and the numerous studies in progress for cancer immunotherapies, only two clinical trials have been initiated for anti-HIV CAR T cells (NCT 03240328 and NCT 01013415). In this review, we will provide an overview of the different CAR T-cell strategies that have been attempted, the lessons learned from earlier trials, and challenges that remain to be addressed before bringing CAR T cells to HIV þ patients.
EARLY ADOPTIVE T-CELL THERAPY FOR HIV-1 TREATMENT
The basic concept of CAR-based therapies targeted against HIV-1 dates to studies initiated in the late 1980s. For example, soluble CD4 molecules were tested as blocking agents designed to prevent HIV infection and viral replication by interfering with the essential interaction between cell surface CD4 and the viral envelope, but had limited efficiency because of the short-serum half-life of soluble CD4, as well as viral resistance in primary HIV-1 isolates [2, 3] . To improve this strategy, cytolytic CD8 þ T cells (CTLs) were engineered to express chimeric proteins, including combinations of the extracellular domain of CD4 with the transmembrane and intracellular signaling domains of T-cell IgG Fc receptors (CD4z-CAR [4] ), Tcell receptors (TCRs) or the variable regions of isolated monoclonal antibodies [5] [6] [7] . By combining an extracellular domain to recognize HIV antigen with an intracellular signaling domain, these constructs efficiently lysed envelope-expressing cells in vitro. Prior to initiation of clinical trials, only one study validated such strategies in vivo, in immunodeficient mice using gene-modified hematopoietic stem and progenitor cells (HSPC) [8] . These studies were reviewed recently [9 & ].
In pioneering clinical trials, adoptive transfer of gene-modified HIV-specific T cells did not significantly impact viremia in vivo because of lack of T-cell persistence [10] [11] [12] [13] [14] [15] . The subsequent trials built on studies in cytomegalovirus (CMV)-infected patients, which demonstrated that the lack of persistence of adoptively transferred CTLs was because of the absence of supporting CD4 þ T cells [16] . By using both CD4 þ and CD8 þ T cells, circulating CD4z-CARmodified T cells persisted for more than 10 years postinfusion in clinical trial patients who participated in long-term follow-up studies, without evidence of toxicities or transformation [11, [17] [18] [19] (NCT01013415). Unfortunately, cells persisted at a low frequency (average of 0.01-0.1% circulating CD4z-CAR cells), and the impact on HIV viremia was low [11, [17] [18] [19] .
Multiple technical parameters may have limited the efficacy of early CAR trials, but have been addressed more recently in the setting of hematological malignancies. These include low-vector transduction efficiencies, the need for CD4 þ T-cell help, suboptimal CAR constructs, and inadequate ex vivo cell manipulation. Thus, applying these advances to HIV CAR therapies will likely also have a significant impact on the treatment of HIVinfected patients.
DESIGNING THE ANTI-HIV CHIMERIC ANTIGEN RECEPTOR PROTEIN
The 'first generation' CAR constructs employed in the early trials described above contained a single intracellular signaling domain derived from the CD3z chain of the TCR, fused either to the extracellular region of CD4 (CD4z-CAR), or to the variable region of isolated monoclonal antibodies (singlechain variable fragment, scFv-CAR; reviewed in [20 & ]). These CARs proved to be sensitive to the size of the spacer that separated this domain from the cell surface, impacting not only the conformation and affinity of the chimeric protein but also its expression and stability [21] . More recent studies employed CD4z-based or scFv-based chimeric proteins with second-generation or third-generation CARs, which contained one or two intracellular costimulatory domains, respectively, and were recently reviewed [9 & ]. The essential interaction between HIV-1 envelope and the CD4 protein has been exploited in the design of the early CARs, ensuring broad targeting of all HIV-1 isolates. Recent studies have validated CD4z-CARs in vitro [22, 23] ] demonstrated some variations in breadth and potency and suggest that some antibody-derived scFVs might be more adapted than others for CAR T-cell applications. Importantly, it remains unclear, which assay is the best predictor of in vivo CAR T-cell efficiency. Nevertheless, these studies make clear that the bNAb choice is critical to the functionality of HIVspecific CARs, and requires a broad, apples-to-apples comparison.
A combination or 'bi-specific' CAR may be required to address the well characterized capacity of HIV-1 to mutate and escape therapeutic and/or host immune responses, leading to inefficient T-cell responses and viral escape, instead of controlling virus replication [15, 33] Comparisons between antibody-based CARs and transgenic TCR-expressing CTLs provided useful insights into the importance of affinities and avidities into CAR T-cell activities, as excessively high affinities (e.g. using bNAb-based CARs) might be detrimental to CTL activity [36] . Lower affinities might be optimal for antigen-scFV CAR interactions, which could be explained by serial interactions required for the formation of the immunological synapse mediating cytolysis, as demonstrated in the case of TCR interactions with major histocompatibility complex (MHC) molecules [34, 37, 38] . Lowaffinity CAR proteins can exhibit improved activity and specificity especially in the presence of lowantigen expression [36, 39] , as is observed with HIV-1 ( Fig. 1 ). These insights into the dynamics of protein interactions involved in CAR efficiency strongly suggest that the affinities of the selected antibodies when designing a CAR construct should be considered. Additionally, in the case of CARexpressing stem cells undergoing thymic selection (see below), the affinity of the chimeric protein Relative to other cell types in which retroviral vector engineering introduces risks of oncogenic transformation, CAR-modified T-cell products are more stable and low-risk, especially for HIV patients requiring long-term persistence of the treatment [17, 40] ] and practical limitations, that is, risks associated with patients with active plasma viremia, will most likely limit initial HIV CAR trials to stably suppressed, ARTtreated patients. CAR T cells persisted long-term (over a decade) in suppressed patients, possibly because of viral blips in peripheral blood and/or persistent viral antigen in secondary lymphoid tissues. These sources of infrequent, ongoing antigen expression could facilitate restimulation and expansion of CAR-expressing cells; however, the low frequency of CAR T cells and modest effect on viremia suggest that higher antigen expression might be necessary for therapeutically relevant levels of CAR T-cell expansion [17] . Although these dynamics may be improved with second-generation and third-generation CARs, improving CAR T-cell persistence in the absence of antigen expression will be required, especially with the goal of life-long therapy to protect against recrudescent virus that may appear years after remission.
Lack of functional HIV-specific CD4 þ T cells also contributes to low CAR T-cell persistence [55, 56] . Prior to CAR modification, enrichment/selection for T cells with a memory phenotype and retention of CD4 þ T cells in the infused T-cell product improve T-cell expansion and persistence in vivo (for a review, see [57] ). Rational selection of cytokines during Tcell culture, for example, favoring IL7 and IL15 over IL2, may also aid in the generation of a more robust T-cell product [58,59 && ]. T-cell exhaustion could also be targeted; similar to cancer patients, HIV-infected individuals' T cells express higher levels of PD1 [60, 61] , Tim3 [62] and other exhaustion markers.
Blockade of these pathways could have a binary action by increasing the immune response [63,64 & ,65] whereas more effectively targeting latently infected cells [66] . Finally, HSPC-derived CAR cells should also address the problem of T-cell persistence, by providing a lifelong source of T-cell progenitors that give rise to functional CAR T-cells in an antigen-dependent manner [25 && ]. Viral escape because of mutations in HIV-1 envelope, and lack of effective T-cell stimulation by these mutated epitopes, may also underlie low levels of CAR T-cell persistence in future trials [15] . Identifying epitopes expressed in latently infected reservoir cells, ideally those that are essential to virus fitness [67, 68] , should minimize selection for potential escape mutations.
Off-target effects, toxicities, and infectionresistant chimeric antigen receptor cells 
CONCLUSION
CAR therapies, born in part as a treatment for HIV, represent arguably the most important clinical treatment for cancer developed in decades. Due to a rapidly increasing knowledge base, CARs are poised to make a powerful impact in infectious disease settings such as suppressed HIV infection as well. CAR therapy for HIVþ patients should keep in mind common ground with cancer CARs but also recognize unique aspects. For example, unlike cancer indications, where alternative therapies are frequently unavailable, HIV CAR patients will need to be treated with particular attention to safety, given that these patients can live an almost normal life on ART. Despite the increasing numbers of clinical trials assessing CAR T cells for cancer immunotherapy and recent FDA approval of these treatments, the lessons learnt from these studies must be more aggressively translated to the HIV field, as only two clinical trials are now assessing CAR T cells for HIV-infected patients (NCT 03240328 and NCT 01013415). Although several obstacles remain to be addressed, new CAR engineering, cellular manufacturing, and subset targeting strategies have the potential to overcome these hurdles, enabling safe, efficient, and specific clearance of HIVþ targets in vivo.
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